DocDollars

Amag Pharmaceuticals, Inc.

MA · United States · Reporting entity ID 100000010948

Total reported 2019–2025
$10.3M
#480 of 2,960 reporting companies — 0% of all reported industry payments
$3.34M in general payments across 25,453 records, plus $6.99M in research funding across 1,311 records.

How it breaks down

General payments $3,337,635
Research funding $6,992,966

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Amag Pharmaceuticals, Inc. reported $10.3M to US doctors and teaching hospitals from 2019 to 2025, ranking #480 of 2,960 reporting companies. 68% of that was research funding and 32% general payments such as consulting, speaking, food and travel. 25,453 general payment records and 1,311 research records were filed.

Common questions about Amag Pharmaceuticals, Inc.

How much has Amag Pharmaceuticals, Inc. paid US doctors?

Amag Pharmaceuticals, Inc. reported $10,330,601 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $3,337,635 in general payments, $6,992,966 in research funding.

How does Amag Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #480 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Amag Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.